We report a case of primary large B cell-type pituitary lymphoma in a 47-year-old immunocompetent female who presented with headache and cranial nerve palsy. She was treated with the DeAngelis chemotherapy protocol and achieved a complete remission. At 1 and 6 months after completion of chemotherapy, she presented with anasarca and was diagnosed with relapse exclusively in the bone marrow twice. She received 8 cycles of R-CHOP chemotherapy and had complete resolution of anasarca. Consequently, we proceeded with salvage chemotherapy followed by autologous stem cell transplantation. To our knowledge, this is the first reported case of primary pituitary lymphoma that relapsed exclusively in the bone marrow and presented with clinical findings of idiopathic anasarca.

Helle TL, Britt RH, Colby TV: Primary lymphoma of the central nervous system. J Neurosurg 1984;60:94–103.
Fine HA, Mayer RJ: Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093–1104.
Freda PU, Post KD: Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am 1999;28:81–117.
Baumgartner JE, Rachlin JR, Beckstead JH, Meeker TC, Levy RM, Wara WM, Rosenblum ML: Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990;73:206–211.
Huang YY, Lin SF, Dunn P: Primary pituitary lymphoma presenting as hypophysitis. Endocr J 2005;52:543–549.
Giustina A, Gola M, Doga M, Rossei E: Clinical review 136. Primary lymphoma of the pituitary: an emerging clinical entity. J Clin Endocrinol Metab 2001;86:4567–4575.
Mathiasen R, Jarrahy R, Cha S, Kovacs K, Herman V, Ginsberg E, Shahinian H: Pituitary lymphoma: a case report and literature review. Pituitary 2000;4:283–287.
Liu JK, Sayama C, Chin SS, Couldwell WT: Extranodal NK/T-cell lymphoma presenting as a pituitary mass. J Neurosurg 2007;107:660–665.
Armitage JO, Longo DL: Clinical features, treatment, and prognosis of specific lymphoid malignancies; in Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson J, Loscalzo J (eds): Harrison’s Principles of Internal Medicine, ed 15. New York, McGraw-Hill, 2001, pp 719–727.
Aho R, Ecfor T: Pathogenesis of primary central nervous lymphoma: invasion of malignant lymphoid cells into and within the brain parenchyma. Acta Neuropathol 1993;86:71–76.
Paulus W, Jellinger K: Human herpesvirus-6 and Epstein-Barr virus genome in primary cerebral lymphoma. Neurology 1993;43:1591–1593.
Kuhn D, Buchfelder M: Intrasellar malignant lymphoma developing within pituitary adenoma. Acta Neuropathol 1999;97:311–316.
Fleming WH, Murphy PR, Murphy LJ, Hatton TW, Matusik RJ, Friesen NG: Human growth hormone induces and maintains cmyc gene expression in Nb2 lymphoma cells. Endocrinology 1985;117:2547–2549.
Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Ezzat S: Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995;80:2302–2311.
DeAngelis LM: Current management of primary central nervous system lymphoma. Oncology 1995;9:63–71.
Massier A, Scheithauer BW, Taylor HC, Clark C, Llerena L: Sclerosing eipthelioid fibrosarcoma of the pituitary. Endocr Pathol 2007;18:233–238.
Nieder C, Mehta MP, Jalali R: Combined radio and chemotherapy of brain tumors in adult patients. Clin Oncol 2009, in press.
Imai H, Shimada K, Shimada S, Abe M, Okamoto M, Kitamura K, Kinoshita T, Shiraishi T, Nakamura S: Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma. Pathol Int 2009;59:431–437.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.